USP13 and neoplasm: To determine whether spautin-1 as a USP13 inhibitor could sensitize tumor cells to ABT-263, we performed dose matrix experiments containing a range of drug concentrations and analyzed the effects of combining ABT-263 and spautin-1 using the Bliss independence model41.